Sol-Gel Technologies' SGT-210 Fails to Show Efficacy in Darier Disease Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Source: Globenewswire
- Clinical Trial Outcome: Sol-Gel Technologies' Phase 1b study of SGT-210 for Darier disease failed to demonstrate efficacy over the vehicle control, leading to the decision not to advance the drug, indicating a significant shift in R&D strategy.
- Resource Reallocation: The company plans to pursue small, low-cost feasibility studies in other areas of unmet medical need, aiming to optimize resource allocation and mitigate R&D risks in light of recent trial results.
- Focus on Key Projects: Sol-Gel will continue to prioritize the Phase 3 trial of SGT-610 for Gorlin syndrome, which, if successful, could become the first treatment to prevent basal cell carcinoma in these patients, representing significant market potential.
- Market Challenges: The failure of SGT-210 places Sol-Gel under increased competitive pressure in the dermatology market, potentially affecting its future investment appeal and shareholder confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLGL
Wall Street analysts forecast SLGL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLGL is 50.00 USD with a low forecast of 50.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 60.850
Low
50.00
Averages
50.00
High
50.00
Current: 60.850
Low
50.00
Averages
50.00
High
50.00
About SLGL
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
- Stock Performance: Palvella Therapeutics saw its stock surge from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, reflecting strong market potential in rare disease treatments.
- Product Development: Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and other rare diseases, with potential FDA approval expected to unlock a multi-billion-dollar market opportunity, further solidifying the company's position in the biopharmaceutical sector.
- Acquisition Activity: Cidara Therapeutics agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion, with the deal expected to close in Q1 2026, highlighting major pharmaceutical interest in innovative therapies.
- Clinical Progress: Celcuity's Gedatolisib submitted a New Drug Application to the FDA in November 2025 for HR+, HER2- advanced breast cancer, which, if approved, would significantly enhance its competitive edge in the oncology market.
Continue Reading
What’s Causing the Decline of Small Cap Sol-Gel Tech Stock Today?
Clinical Study Update: Sol-Gel Technologies announced that the Phase 1b study of SGT-210 for Darier disease did not show efficacy compared to the vehicle, leading to a decision not to advance further in this indication. The company plans to conduct small feasibility studies in other areas of unmet medical need.
Focus on Other Programs: The Executive Chairman, Mori Arkin, emphasized the company's commitment to completing the Phase 3 program for SGT-610 in Gorlin syndrome and preparing for a potential Phase 3 program in high-frequency basal cell carcinoma, contingent on the success of the Gorlin trial.
Stock Performance Analysis: Sol-Gel Technologies (SLGL) is currently showing strong technical indicators, trading above key moving averages, with a bullish trend supported by positive momentum in the MACD and a neutral RSI.
Recent Stock Movement: SLGL stock experienced a decline of 6.81% to $39.26, while over the past year, it has gained 735.02%, indicating a strong upward trajectory but caution is advised as it approaches resistance levels.
Continue Reading